Authors
Latest:
Dr Sartor on PSMA PET and Radioligand Therapy in Prostate CancerOliver Sartor, MD, discusses the use of PSMA PET and radioligand therapy in prostate cancer.
Latest:
Next-Generation Sequencing Analysis of Circulating Tumor DNAOliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.
Latest:
HIPEC for Ovarian Cancer: An Exciting Locoregional StrategyApproximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.
Latest:
Dr. Pagani Discusses Aromatase Inhibitors for Premenopausal Women with Breast CancerOlivia Pagani, MD, Institute of Oncology, Southern Switzerland, discusses the result of a joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptor–positive (HR+) breast cancer who were treated with the aromatase inhibitor exemestane.
Latest:
Dr. Olopade on Moving the Needle Forward in Preventive Oncology and GeneticsOlufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.
Latest:
Novel Therapies for T315I-Mutant Chronic Myeloid LeukemiaAbelson tyrosine kinase (ABL1) is a nonreceptor tyrosine kinase involved in cell growth and proliferation.
Latest:
Signs Point to Better Market Conditions for BiosimilarsEven though many challenges must be overcome before widespread adoption can occur, there is still much promise on the horizon for biosimilars.
Latest:
Improving Care in Multiple Myeloma: Unmet Needs and Future DirectionsClosing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.
Latest:
Dr Hamid on the Investigation of Fianlimab With Cemiplimab in Advanced MelanomaOmid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.
Latest:
Dr Hamid on Addressing Unmet Needs in Relapsed Melanoma With LifileucelOmid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.
Latest:
OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Announce Recipients of the 2024 Luminary Awards in GI CancersOncLive and the Ruesch Center for the Cure of GI Cancers announce the winners of the 2024 Luminary Awards in GI Cancers.
Latest:
Noninvasive Stool Test Effectively Detects Colon CancerThe iFOBT test examines the stool for hidden blood, which could come from anywhere in the GI tract, and possibly indicates a colon tumor or precancerous growths known as polyps.
Latest:
The OncFive: Top Oncology Articles for the Week of 11/17Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.
Latest:
FDA Accepts Sacituzumab Govitecan Application for TNBCThe FDA has accepted a biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies for metastatic disease.
Latest:
Dr Grunwald on a Real-World Study of Risk Factors For Disease Progression in PVMichael R. Grunwald, MD, discusses findings from a real-world study of risk factors related to disease progression in polycythemia vera.
Latest:
ASCO Updates Guidelines on Bone-Modifying Drugs in Breast CancerASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.
Latest:
Age Cutoff for Pap Tests QuestionedMore than 12% of newly diagnosed cervical cancers occurred in women aged 70 to 85 years during 2000 to 2006
Latest:
Study Shows No Survival Benefit of Cetuximab Over Cisplatin-Based Chemoradiation in Head and Neck CancersPatients with locally advanced head and neck cancer gained no survival benefit with the addition of cetuximab to chemoradiation.
Latest:
Dr. Ginsburg Discusses Cervical Cancer Screening TechniquesOphira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses cervical cancer screening techniques.
Latest:
Dr. Ginsburg on Genetic Testing in Ovarian Cancer FamiliesOphira M. Ginsburg, MSc, MD, FRCPC, director of the High-Risk Cancer Program, Perlmutter Cancer Center at NYU Langone Medical Center, discusses the importance of genetic testing in ovarian cancer families.
Latest:
Dr. Ginsburg on Determining Genetic Testing in Gynecologic MalignanciesOphira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.
Latest:
Dr. Caffo Discusses Enzalutamide/Docetaxel Combination in Frontline mCRPCOrazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses enzalutamide plus docetaxel combination for the frontline treatment of metastatic castration-resistant prostate cancer.
